S‐1 Plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial

Oncologist - United States
doi 10.1634/theoncologist.2018-0901
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Phase I Trial of Oxaliplatin Plus S-1 Chemotherapy in Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2010English

A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Correction: A Phase II Trial of 1st-Line Modified-Folfoxiri Plus Bevacizumab Treatment for Metastatic Colorectal Cancer Harboring RAS Mutation: JACCRO CC-11

Oncotarget
Oncology
2018English

Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease

Current Oncology
Oncology
2019English

A Phase II Trial of Fixed-Dose Rate Gemcitabine Plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

Oncology
MedicineCancer ResearchOncology
2012English

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Oncologist
Cancer ResearchMedicineOncology
2019English

A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy